Keros Therapeutics, Inc. Financials

Market Capitalization $546.3 Million as of July 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-2.28
Forward PE	-3.30
Price to Sales TTM	$1171.67
Price to Book MRQ	$1.39
Enterprise to Revenue	386.11
Enterprise to EBITDA	-1.24

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	-15117.78%
Return on Assets TTM	-28.17%
Return on Equity TTM	-43.82%

Income Statement

Revenue TTM	$651,000
Revenue per Share TTM	$0.02
Quarterly Revenue Growth	4750.00%
Gross Profit TTM	$0
EBITDA	$-202,890,000
Net Income to Common TTM	$-181,570,000
Diluted EPS TTM	$-5.22
Quarterly Earnings Growth YoY	4750.00%

Balance Sheet

Total Cash MRQ	$530,684,000
Total Cash per Share MRQ	$13.10
Total Debt MRQ	$
Total Debt to Equity MRQ	3.62
Current Ratio MRQ	19.03
Book Value per Share MRQ	$13.57

Cash Flow

Operating Cash Flow TTM	$-140,320,000
Levered Free Cash Flow TTM	$-89,324,248

KROS Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	40,507,400
Float Shares	35,371,070
Avg 10 Volume	2,387,330
Avg 30 Volume	None
Shares Short	2,197,295
Short Ratio	5.28
Short % of Shares	7.39%
% Held by Insiders	5.43%
% Held by Institutions	100.90%

Stock Price Summary

Beta	1.24
Fifty Two Week Low	$9.78
Fifty Two Week High	$73.00
Fifty Two Week Change	-392.82%
Day 50 MA	$59.16
Day 200 MA	$55.11

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date